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Abstract
Background: The objective is to estimate the cost-effectiveness of an intervention that reduces hospital re-admission
among older people at high risk. A cost-effectiveness model to estimate the costs and health benefits of the intervention
was implemented.
Methodology/Principal Findings: The model used data from a randomised controlled trial conducted in an Australian
tertiary metropolitan hospital. Participants were acute medical admissions aged .65 years with at least one risk factor for
re-admission: multiple comorbidities, impaired functionality, aged .75 years, recent multiple admissions, poor social
support, history of depression. The intervention was a comprehensive nursing and physiotherapy assessment and an
individually tailored program of exercise strategies and nurse home visits with telephone follow-up; commencing in
hospital and continuing following discharge for 24 weeks. The change to cost outcomes, including the costs of
implementing the intervention and all subsequent use of health care services, and, the change to health benefits,
represented by quality adjusted life years, were estimated for the intervention as compared to existing practice. The mean
change to total costs and quality adjusted life years for an average individual over 24 weeks participating in the intervention
were: cost savings of $333 (95% Bayesian credible interval $ -1,932:1,282) and 0.118 extra quality adjusted life years (95%
Bayesian credible interval 0.1:0.136). The mean net-monetary-benefit per individual for the intervention group compared to
the usual care condition was $7,907 (95% Bayesian credible interval $5,959:$9,995) for the 24 week period.
Conclusions/Significance: The estimation model that describes this intervention predicts cost savings and improved health
outcomes. A decision to remain with existing practices causes unnecessary costs and reduced health. Decision makers
should consider adopting this program for elderly hospitalised patients.
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Introduction
Hospital bed days are a valuable economic commodity. In 2004/05
Australian policy makers allocated expenditures of $14,470 (AUD)
million to supply 14,391 hospital bed days, yet waiting lists continue to
grow. In 2004/05 ninety percent of patients were admitted for elective
surgery within 217 days compared to 197 days in 2002/03 [1]. The
adoption of novel health programmes that reduce risk of hospital re-
admission are worth considering on economic grounds. Programmes
will incur a positive cost to implement but cost savings may arise after
adoption and extra health benefits may result from reduced morbidity
and mortality risk. The overall change to costs and benefits need to be
weighed up, and for this purpose health economists have developed
evaluation methods.
The basics of economic evaluation in healthcare are described by
Donaldson et al. [2] and Drummond et al. [3] provide a useful text
book. The concept of opportunity cost is the mainstay. This shows
that using scarce resources for one programmeincurs a cost, because
an opportunity to pursue some other beneficial programme is lost.
An efficient outcome is when resources are allocated across
programmes such that opportunity cost is minimised, which is
analogous to benefit being maximised. Providing healthcare decision
makers with information about the changes to costs and benefits
from adopting different health programmes can improve efficiency.
A primary method for economic evaluation is cost-benefit
analysis that summarises in monetary values the gains and losses
from adopting a novel health programme. If costs are found to be
less than the benefits then the programme is desirable, and
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The advantage of this approach is that all manner of different
outcomes, some non-health related, can be included in an
evaluation. The findings should represent an aggregation of the
values of all members of society and provide information about
opportunity cost. There are difficult challenges however for the
analyst who attempts to find monetary valuations for costs and
benefits that change with the adoption of a new health
programme. Individuals find it difficult to reveal accurately how
they value health improvement in monetary terms [5], and, those
with more money may give different responses, skewing the
allocation of resources toward the wealthy [6]. A number of cost-
benefit analyses of health care programmes have been published in
the medical and economics literature and these have been
reviewed [7,8].
Another method for economic evaluation is cost-effectiveness
analysis. In this case the analyst does not seek a monetary
valuation of health benefit but counts benefit in natural units of
outcome such as years of life saved, pain free days or quantifiable
improvements in symptoms. This method is easier to apply and
disseminate. A disadvantage is that the connection with opportu-
nity costs is severed as individual valuations are not included. It
has been suggested that cost-effectiveness analyses can only
address questions about whether the same level of health output
can be achieved at lower cost [2]. Cost-effectiveness analysis may
be less useful than cost-benefit analysis because it cannot directly
address questions about how resources are allocated between
programmes.
A special type of cost-effectiveness analysis is cost-utility analysis.
The analyst measures health benefit by quality adjusted life years
(QALYs). These are extra years of life gained from a novel
programme weighted by a preference based value between zero
(dead) and one (good health) [9]. Five years of extra life valued at
0.5 per year by individuals will equal 2.5 QALYs. Decision makers
may be attracted to programmes that provide a cheaper marginal
QALY. An advantage of cost-utility analysis is that the weighting
score, that updates the number of QALYs gained, represents
individual preferences or utilities [10]. This allows decision makers
to pursue the objective of maximising health gain (QALYs) from a
fixed pot of health resources. This approach to decision making in
healthcare is called extra-welfarism and has been embraced by the
institutional regulators of publically funded health care systems in
the UK [11] and Australia [12], as well as in other settings. The
decision rule can be summarised in simple terms. If the change in
health costs (DC) divided by the change in QALYs (DE) is less than
some threshold value that health decision makers are willing to pay
for the marginal QALY (c), then the programme is cost-effective
and should be adopted:
DC=DE ðÞ v c
It is useful to consider uncertainty in health decision making
[13] and ratios have awkward statistical properties. This is resolved
by rearranging the same information to calculate a net-monetary-
benefit statistic [14]:
DE   c ðÞ {DC
This provides a linear outcome, rather than a ratio, and
facilitates quantitative analyses of data that are easier to interpret
for decision making [15].
Cost-utility analyses do not provide the same information that
would arise from a cost-benefit analysis, for which the analyst
elicits individual valuations of outcomes. Instead, the value per
QALY (c) arises from a judgement made by government or some
quasi-government agency who aim to maximize health from
scarce resources [16]. Health economists debate the merits of the
different approaches to economic evaluation [17]. If decision
makers want the largest public benefit then cost-benefit analysis is
preferred as opportunity costs are made explicit; but valuing
individual preferences for health in money terms is problematic
[5,6]. If decision makers aim to maximise the amount of health
gain (i.e., QALYs) from a fixed pot of health resources then the
cost-utility analysis approach may be useful [18]. Birch and Gafni
[19] make an important point that cost-utility analyses tend to
focus on individual programmes rather than opportunity cost, and
so the important issue of affordability is neglected. Instead of
thinking about affordability, decision makers working with cost-
utility information use the maximum willingness to pay for a
marginal QALY (c) as a decision rule. This value varies in
practice, often to accommodate other important objectives such as
equity and fairness [11]. Some argue it is arbitrary and that extra-
welfarism is unlikely to lead to an optimal allocation of healthcare
resources [20]. Solutions have been proposed that utilise a
mathematical programming method [21] and this method has
been applied to a real resource allocation problem [20]. If cost-
utility analysis is used to guide decisions then the impact on the
overall health budget should be described and the issue of
affordability made explicit [2,22].
The aim of this paper is to describe a cost-utility analysis of a
decision to adopt a novel health programme that has been shown
to reduce re-admissions to hospital among an elderly and high risk
group. The data arise from a randomised controlled trial of the
intervention conducted in an Australian setting [23]. The analyses
are motivated by an extra-welfarist goal of maximising health
benefits from a health budget. The research question is whether
scarce healthcare resources should be allocated to provide this
intervention, or whether remaining with existing practice is a
better decision. The implications of using cost-utility analysis to
address this policy question are discussed. Older adults have
higher rates of hospital admission and re-admission than the
general population in Australia [24] the UK [25] and the US [26].
Preventing emergency re-admissions among older patients is one
way to ease pressure on beds in acute hospitals and save costs. A
recent randomised controlled trial conducted in an Australian
setting showed an intervention was effective at preventing
emergency re-admission to hospital among older people with
known risk factors for re-admission [23]. The economic outcomes
of adopting this intervention have not been described and may
provide useful information for health decision makers.
Methods
The aim of the primary trial was to measure the effect of an
intervention targeting patients at high risk of hospital re-admission
on health service utilisation, health-related quality of life, general
health, psycho-social outcomes and functional ability. Participants
were recruited into the trial within 72 hours of hospital admission
and randomised to intervention or control group. The control
group (n=64) received the routine discharge planning and
rehabilitation advice, this is defined as usual care. The intervention
group (n=58) received additional intervention described in detail
by Courtney et al. [23]. Within 72 hours of admission a nurse and
a physiotherapist made a comprehensive patient assessment and
together wrote an individual post-discharge care plan. This
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programme of muscle stretching, balance training, walking for
endurance, and muscle strengthening using resistance exercises.
During the inpatient stay the nurse visited patients every day to
address concerns, facilitate the exercise program, and oversee
discharge planning. Written guidelines were provided on post-
discharge management, including diagrams and specific instruc-
tions for their exercise program. Within 48 hours of discharge the
nurse visited the patient in their home to assess their progress.
Extra home visits were provided if required. One telephone call
was provided each week for four weeks, followed by monthly calls
until 24 weeks. The nurse was also available for contact between 9
a.m. and 5 p.m. weekdays. Issues that might impede adherence
and progress were addressed during the telephone follow-up. Data
that describe patient outcomes were collected at baseline and then
at 4, 12, and 24 weeks after discharge.
The mean age of the groups was 78.1 years for intervention and
79.4 for controls; 36% and 40% were male, mean lengths of stay
were 4.6 and 4.7 days and frequencies of co-morbidities and risk
factors for re-admission were similar. Baseline characteristics are
reported by Courtney et al. [23]. There were significantly fewer
emergency hospital re-admissions among the intervention group
(22% of intervention group, 47% of control group, p=.007) and
significant fewer emergency GP visits (25% of intervention group,
67% of control group, p,.001). The intervention group showed
significantly greater improvements in quality of life over the
control group as measured by the SF-12v2 health survey.
The perspective for the cost-effectiveness model was the health
care provider in the Australian setting and costs to patients and
informal were not measured, nor were productivity changes. The
patient level data collected by Courtney et al. [23] were used
alongside other routinely available data to inform a decision
analytic cost-effectiveness model. The modelling process com-
pared a decision to adopt the novel intervention as compared to a
decision to remain with a usual care alternative (i.e. the control
group in the trial). The progress of all patients after discharge from
a primary hospital admission was described using a Markov state-
transition process [27] shown in Figure 1. The advantage of a
Markov model is that it can quantify a decision problem that
involves risk over time, when the timing of events is important and
when important events may happen more than once [28]. As time
moves forward patients face some probability of remaining at
home, transitioning to a community care facility, being re-
admitted to hospital or dying. Transition to a community care
facility and death are one way moves whereas patients can cycle in
and out of hospital up to three times during the 24 weeks of the
study. The model updates every day for a period of 24 weeks after
discharge. All transition probabilities are labelled in Figure 1. For
each day in the model costs and health benefits (QALYs)
accumulate based on the patient level data collected by Courtney
et al. [23]. The cost and QALY outcomes are summed at the end
of the 24 week trial and a comparison drawn between the patients
who received the intervention and those who received usual care.
The difference in costs (DC) and QALYs (DE) are combined with
valuations of the willingness to pay for a marginal QALY (c)t o
estimate net-monetary-benefits for a decision to adopt the
intervention (i.e., (DE*c)-DC)). The maximum willingness to
pay for a QALY was assumed to be $64,000 for the Australian
setting [29].
All cost outcomes are reported in 2008 Australian dollars. The
costs of the intervention were incurred during the primary hospital
admission and then after discharge. The primary admission costs
Figure 1. State transition Markov model.
doi:10.1371/journal.pone.0007455.g001
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each patient and prepared an individual exercise plan for them to
take home. The post-discharge costs include a single home visit by
a programme nurse and ten follow up calls of 20–30 minutes each
over 24 weeks. Patients were also given an exercise stretchy band
and pedometer to assist with the prescribed physical activities.
After discharge from the primary admission the costs of GP visits,
hospital emergency department visits or utilisation of ‘other’ health
care services such as physiotherapy, home help and community
nursing were included. The number of days spent in hospital
following a re-admission to hospital or admission to a community
nursing facility was included, and the relevant cost per day
applied. Values for all cost parameters are shown in Table 1.
The SF-12 health survey outcomes collected at baseline, 4, 12
and 24 weeks were mapped onto EQ-5D utility values using an
algorithm developed by Gray et al. [30]. This estimates a utility
score between zero and 1 to describe the value of the health state
of patients. These utility scores were profiled over the 24 weeks of
the study to estimate the number of quality adjusted life years
(QALYs). The risk of death observed among the sample was used
to describe the risks of death for all model participants.
Uncertainties in the data were propagated forward to the results
by fitting probability distributions to each parameter. Beta
distributions were fitted to all transition probabilities and gamma
distributions to all cost parameters. Uniform distributions were
fitted to parameters where only two data points were available that
describe a high and low value. One thousand random re-samples
were taken from all distributions. This gave rise to 1000 estimates
of the change to total cost (DC), change to total QALYs (DE) and
net-monetary-benefit. The probability the intervention was cost-
effective as compared to the usual care alternative was estimated
by counting the number of times the net-monetary-benefit statistic
was positive over the total number of re-samples [31]. These
results were plotted as cost-effectiveness acceptability curves that
show the probability that adopting the intervention is a cost-
effective decision, given uncertainties in model parameters. Cost-
effectiveness acceptability curves describe a wide range of decision
maker’s willingness to pay for QALYs (c). Detailed information
about the use and interpretation of cost-effectiveness acceptability
curves is available [31,32]. The process captures the variance in
the data collected from trial participants and accounts for any
correlations between parameters. The method used to fit beta,
gamma and uniform distributions to the data and the method used
estimate daily probabilities is described in the Appendix S1.
Results
The mean cost of delivering the intervention was $547 (95%
Bayesian credible interval $470:$626) per individual. The mean
daily probabilities of re-admission to hospital for the intervention
and usual care conditions during the 24 weeks after primary
discharge are shown in Table 2. Between week 1 and week 4 the
usual care condition faced a higher daily probability of a first re-
admission to hospital. There were zero second or third re-
admissions. Between week 5 and 12 the usual care group faced a
marginally lower daily probability of a first re-admission, but a
higher probability of a second re-admission. Between week 13 and
24 the usual care group faced a higher probability of a first and
third re-admission, but not for the second re-admission. For the
entire 24 week period the daily probabilities of transitioning into a
community care facility were 0.00039% for the usual care group
and 0.00016% for the intervention group. The use of non-hospital
based health services were higher for the usual care condition
across all time periods and types of services, with the exception of
‘Visits to Emergency Department’ during weeks 1 to 4 after
discharge. During this time period the intervention group used
more services than the usual care condition. These results are
shown in Table 3.
The number of days the average individual spent in a hospital
bed and a community care facility for the intervention and usual
care conditions are shown in Figure 2 for the 24 weeks of data
collection; the mean difference in the number of bed days used for
this time period is 0.48 days. For the average individual,
participating in the intervention for 24 weeks reduced costs by
$333 (95% Bayesian credible interval $-1,932:1,282) and increased
QALYs by 0.118 (95% Bayesian credible interval 0.1:0.136). The
mean net-monetary-benefit per individual for the intervention
group compared to the usual care condition was $7,907 (95%
Bayesian credible interval $5,959:$9,995) for the 24 week period.
Uncertainties arising from the parameters used in the modelling
are shown in Figure 3. This reveals clear improvement among
Table 1. Data Used to Estimate Costs of Delivering the Intervention per Patient, all costs in 2008 $AUD.
Cost Item Data Used Source
Assessment by Physiotherapist Consultation between 80 and 150 minutes Notes kept by intervention physiotherapist
Assessment by Nurse Consultation between 30 and 60 minutes Notes kept by intervention nurse
Daily Visits by Nurse Consultation between 10 and 30 minutes Notes kept by intervention nurse
Length of stay for primary admission Mean=4.66 days, St Dev=2.77 days Data collected by Courtney et al. [23]
One off home visit Travel and visit time between 100 and 150 minutes Notes kept by intervention nurse
Ten follow up calls over 6 months Duration of call between 20 and 30 minutes Notes kept by intervention nurse
$10 stretchy band $10 Data collected by Courtney et al. [23]
$10 pedometer $10 Data collected by Courtney et al. [23]
Hourly cost Physiotherapist $52.3 Mater Health Services, salary schedule
Hourly cost senior Nurse (HEWA 7) $50 Mater Health Services, salary schedule
GP, ED and other health care service per visit $50 to $90 Medical Benefits Schedule [44]
Value of bed day in hospital $611 to $1008 Australian Hospital Statistics [45]
Value of bed day in community care facility $108 Data provided by Economics and Health
Services Group (AIHW), and [46]
doi:10.1371/journal.pone.0007455.t001
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QALY values higher for the usual care condition. For the overall
change to cost outcome, 640 out of the 1000 re-samples took a
negative value. The interpretation of these findings is that there is
a 100% probability the intervention delivers higher health benefits
and a 64% chance the intervention saves costs. These are
summarised in the cost-effectiveness acceptability curve included
in Figure 4. The intervention always has the highest change of
being the cost-effective decision, regardless of the value chosen for
health benefits (QALYs).
Discussion
The results show that from a health service perspective net-
monetary benefits are almost $8,000 per individual who is offered
the intervention programme. We expect the opportunity cost to
health services from adopting this intervention to be negligible
because cost savings are likely to compensate the positive costs of
implementing the programme. In this case the impact on the
overall health budget should be neutral and costs may even be
saved; the issue of affordability is not paramount. Gains in health
benefits are enjoyed by those offered the intervention. The results
are robust to the uncertainty among the model parameters used.
The lower Bayesian credible interval for monetary-net-benefits
takes a positive value of $5,959 per individual. Based on the data
available it appears that intervening with a nursing and
physiotherapy assessment and then following up after discharge
is a sensible decision on economic grounds.
The policy implications of this are substantial. In 2005–06 there
were 2,594,755 patient separations from all Australian hospitals
for individuals aged over 65 years (Table 7.6 in Australian
Hospital Statistics [33]). Unpublished data collected for the
original trial [23] showed that close to 50% of the .65 years
population discharged from hospital would meet the eligibility
criteria for the trial (Personal communication, Mary Courtney,
August 6, 2009). This information suggests more than one million
individuals could derive net benefits from receiving this interven-
tion annually.
Other studies have evaluated models of discharge planning and
follow-up care programs for older patients [34–38], yet few
consider whether the intervention is cost-effective. There appears
to be a shortage of cost-effectiveness data in this area. The studies
most frequently reporting cost-effectiveness outcomes are evalua-
tions of transitional care programs for patients with chronic heart
failure. These programs aim to prevent hospital re-admissions and
morbidity in this population, though the program components and
outcomes vary considerably. One report of a program utilizing
regular community nurse home visits for six months following
hospital discharge did not result in significantly decreased re-
admission rates and no economic benefit [39]. Another interven-
tion with nurse-led telephone contacts found decreased hospita-
lization costs, but a slight increase in outpatient department visits
[40]. Two studies reported positive economic outcomes; one with
a program of regular Day Hospital follow-up visits after discharge
in comparison to usual outpatient community care [41]; the other
a more intensive program combining hospital specialist care and
discharge planning, outpatient follow-up visits, nurse phone
follow-up and home GP visits [42]. The Day Hospital follow-up
care resulted in decreased re-admissions, morbidity and mortality;
and incremental cost effectiveness analysis found $1,068 savings
for each quality-adjusted life year gained [41]. The program
combining hospital, outpatient, telephone follow-up and home
visits is similar in scope to the study reported here, and also found
decreased re-admissions and morbidity, with mean cost savings of
Table 3. Mean number (95% Bayesian credible interval in brackets) of consultations with non-hospital services for 24 weeks
following primary discharge for the intervention and usual care conditions.
GP consultations Visits to emergency department All other health contacts #
Week 1 to 4 - Usual care 0.45 (0.26:0.70) 0.12 (0.06:0.21) 1.12 (0.34:2.41)
Week 1 to 4 - Intervention 0.12 (0.04:0.23) 0.18 (0.07:0.31) 0.07 (0.01:0.17)
Week 5 to 12 - Usual care 0.25 (0.12:0.43) 0.17 (0.08:0.28) 0.22 (0.02:0.68)
Week 5 to 12 - Intervention 0.05 (0.01:0.12) 0.03 (0.00:0.09) 0.11 (0.00:0.38)
Week 13 to 24 - Usual care 0.64 (0.41:0.91) 0.12 (0.05:0.23) 0.28 (0.03:0.74)
Week 13 to 24 - Intervention 0.07 (0.02:0.15) 0.07 (0.02:0.15) 0.12 (0.01:0.41)
# contact with the outpatients department, visiting a chemist, physiotherapy, community nursing and home help service.
doi:10.1371/journal.pone.0007455.t003
Table 2. Daily probabilities (95% Bayesian credible interval in brackets) of re-admission to hospital for 24 weeks following primary
discharge for the intervention and usual care conditions.
First re-admission (%) Second re-admission (%) Third re-admission (%)
Week 1 to 4 - Usual care 0.405 (0.395:0.415) Zero re-admissions Zero re-admissions
Week 1 to 4 - Intervention 0.313 (0.303:0.323) Zero re-admissions Zero re-admissions
Week 5 to 12 - Usual care 0.216 (0.211:0.220) 0.281 (0.271:0.290) Zero re-admissions
Week 5 to 12 - Intervention 0.259 (0.254:0.264) Zero re-admissions Zero re-admissions
Week 13 to 24 - Usual care 0.131 (0.128:0.134) 0.077 (0.075:0.080) 0.040 (0.038:0.041)
Week 13 to 24 - Intervention 0.028 (0.026:0.029) 0.188 (0.182:0.194) Zero re-admissions
doi:10.1371/journal.pone.0007455.t002
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doi:10.1371/journal.pone.0007455.g003
Figure 4. Cost-effectiveness acceptability curves.
doi:10.1371/journal.pone.0007455.g004
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an intervention for patients with mixed medical diagnoses, and this
study included all medical patients regardless of age or presence of
risk factors for re-admission. The study of a nurse-led, home-
based, case management intervention for 24 weeks after discharge
found no differences in outcomes, including total costs [43].
There are caveats to this research. Not all costs were considered,
and the perspective of this analysis was the health care provider.
Costs to informal carers such as time spent by friends and family
members looking after participants were not included, nor were
productivity changes among participants. It is possible that the
intervention group incurred higher informal carer costs because
they spent less time in hospital or community care facilities. It is
also likely that with fewer re-admissions and better health
outcomes there were productivity gains among the intervention
group. These values are not described by the data used in this
modelling study. We only followed patients for 24 weeks after
discharge and the benefits of the intervention may reduce after this
time. The question of whether data from a relatively modest
sample are sufficient to generalise to other settings is important.
Answers would emerge from repeating the study using larger
samples. Any biases from the primary trial would however have to
be substantial for the decision to change from simply recruiting a
larger sample.
It is valuable for decision makers to find an intervention that
dominates their existing practice by both measures of cost and
effectiveness. Based on the current data this intervention
represents a ‘win-win’ for policy makers. A decision to remain
with existing practice implies higher cost outcomes and worse
health outcomes and this should not sit well with those who
manage health services. The relatively low cost intervention
appears to save costs and improve health outcomes. Patients are
less likely to be re-admitted to hospital or a community care facility
and this is a major source of cost saving. Uncertainty in these
findings could be reduced by repeating the intervention trial using
a larger sample of individuals. Decision makers in the Australian
setting should consider the economic evidence for adopting this
programme presented here, alongside other factors relevant to the
adoption decision. Others may be interested in evaluating this
decision in other settings as the extent to which these findings can
be generalised is unknown.
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